Navigation Links
3-D model reveals secrets of metastasis

A cancer cell breaks away from a primary tumor and settles in a new location, where it once again divides. Pharmaceutical companies typically use simplistic two-dimensional assays for this process, which is known as metastasis, to evaluate anti-cancer therapeutics. In these assays, cells crawl across the surface of a matrix, traveling in a single plane. But a new study indicates that this approach misses some crucial phenomena.

Working in the labs of Whitehead Member Paul Matsudaira and MIT professor Douglas Lauffenburger, postdoctoral researcher Muhammad Zaman discovered that cells move quite differently in three dimensions. His study, which focused on human prostate tumor cells, appeared this week in the online early edition of Proceedings of the National Academy of Sciences.

"Two-dimensional assays ignore the obstacles that cells face in their natural contexts," explains Zaman, who recently became an assistant professor at the University of Texas at Austin. "In 3D, cells move through a thick jungle of fibers, or "vines"TM, that hinder forward progress."

Cells must either squeeze through or chop up these putative vines to get anywhere. As a result, they move slower in three dimensions.

In an interesting twist, all cells need at least some vines to move, as they latch onto the "branches" with claw-like proteins called integrins and pull themselves forward. When Zaman disabled some of these claws, in a manner analogous to certain anti-cancer drugs, the cells moving across the top of the jungle canopy (in two dimensions) needed a greater number of vines to keep up their pace, while cells plowing through the jungle instead needed vines chopped to maintain the same speed. The complexity of this situation is further increased in that the cells become dramatically sensitive to the stiffness of the vines when the integrins are disabled and consequently tend to squeeze through the vines rather than pushing them aside.


'"/>

Source:Whitehead Institute for Biomedical Research


Page: 1 2

Related biology news :

1. Scientists identify new model Of NK cell development
2. Genrate: a generative model that finds and scores new genes and exons in genomic microarray data
3. Molecular models advance the fight against malaria
4. NYU and MSKCC research provides model for understanding chemically induced cancer initiation
5. Genetic therapy reverses nervous system damage in animal model of inherited human disease
6. Disease progression model of pancreatic cancer developed by Penn researchers
7. A new way to share models of biological systems
8. Understanding biases in epidemic models important when making public health predictions
9. Climate model links higher temperatures to prehistoric extinction
10. Gene therapy advance treats hemophilia in mouse models
11. Targeting a key enzyme with gene therapy reversed course of Alzheimers disease in mouse models

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: model reveals secrets metastasis

(Date:11/6/2009)...in harmony with their arboreal hosts. But new rese...heir trees of choice, the ants can get destructive... in the November issue of the American Naturalist...ve trees, and it reopens a centuries-old debate on...s and certain species of plants and trees have coz...
(Date:11/5/2009)...rded a training grant in the amount of $2,756,719 ...rative Graduation Education and Research Training ...be awarded to Kent State. The grant, which is fund...t of 2009, runs through 2014. , The grant funds ...ic resource sensing (EARS). The purpose of the pro...
(Date:11/4/2009)... turns out, hold the power to help militaries and ...ean up toxic waste on test sites. , Compounds kn... back in World War II and have been used in milita...unds are often used to propel tank shells and act ...h increased knowledge of their environmentally har...
Breaking Biology News(10 mins):Ants are friendly to some trees, but not others 2Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing 2Genomic research will enable greener cleanup of military explosive test sites 2MedCath Names Art Parker Executive Vice President and Chief Financial Officer 58084 1MedCath Names Art Parker Executive Vice President and Chief Financial Officer 58084 2Anthem Blue Cross and Blue Shield Awarded NCQAs Accreditation Status of Excellent 58081 1Anthem Blue Cross and Blue Shield Awarded NCQAs Accreditation Status of Excellent 58081 2One Health Commission Teaming Up With World Rabies Day to Spread the One Health Message 58078 1One Health Commission Teaming Up With World Rabies Day to Spread the One Health Message 58078 2
..., Belgium The changes in our climate, producing e... enormous impact on our crops − to put it br...now concluded a research agreement with Bayer BioS...ter of Bayer CropScience, to look into this proble... to elucidate the mechanisms that indicate how pla...
...m, a rocky mineral is abundant in desert regions w...ut oil and gas fields are common. Writing in Inte... Peter van der Gaag of the Holland Innovation Team...ea of using the untapped energy from oil and gas f... Fresh water resources are scarce and will be more...
...N, Va., June 10 Stanley, Inc. (NYSE:,SXE), a lead...al services,to the U.S. federal government, announ...reement to acquire Oberon Associates, Inc. (Oberon...ormation technology services,company. The purchase...subject to certain working capital and other adjus...
Other Biology News:VIB and Bayer join forces for plant research 2VIB and Bayer join forces for plant research 3Rocky water source 2Stanley to Acquire Oberon Associates 2Stanley to Acquire Oberon Associates 3Stanley to Acquire Oberon Associates 4
(Date:11/5/2009)... Call on Thursday, November 5, 2009 at 4:30 p.m. E...5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceutica...OGXI ) today reported unaudited financial results ...ber 30, 2009 and reviewed the Company,s highlights...g consolidated results reflect the operations of O...
(Date:11/5/2009)...N.Y., Nov. 5 BioSpecific...ceutical company developing first-in-class collage... results for the third quarter ended September 30,...ptember of this year, the FDA,s Arthritis Advisory...2-0, the approval of XIAFLEX(TM) for the treatment...
(Date:11/5/2009)..., Texas, Nov. 5 Wound Ma...ay that it has entered into a Letter of Intent to ...Health Technologies, Inc. (OTC Bulletin Board: VHG...00 in cash and debt, 4,000,000 shares of WNDM and ... on the Veriscrip technology being acquired from V...
(Date:11/5/2009)...alif., Nov. 5 WaferGen B...ing developer of state-of-the-art genetic analysis...Ph.D. has joined the company,s Scientific Advisory...and commercializing novel molecular diagnostics fo...the development of computational biology systems f...
Breaking Biology Technology:OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4
...timicrobial sets the new global standard to er...and lethal,microorganisms commonly found in health... C. difficile, NEWARK, N.J., Aug. ... Ygiene(TM) Hospital Grade antimicrobial against,a... of microorganisms which,represent the major sourc...
...First Diagnostic Test Based on Company,s, microR...dical Center, Approved for C...dite Commercialization of its ... Three Additional microRNA-based Cancer Tests in ... Israel and JERSEY CITY, New Jersey, August 19, Ro...
...NUS(R) Medical,Technologies, Inc. (Nasdaq: VNUS )...ts full year 2008 guidance. The Company has record...nses and certain balance sheet accounts,to record ...ation that were,not appropriately recorded in prio...cial Accounting Standard ("SFAS") No. 123R on Janu...
Other Biology Technology:BioNeutral's Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World 2BioNeutral's Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World 3BioNeutral's Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World 4Rosetta Genomics Reports Second Quarter 2008 Financial Results 2Rosetta Genomics Reports Second Quarter 2008 Financial Results 3Rosetta Genomics Reports Second Quarter 2008 Financial Results 4Rosetta Genomics Reports Second Quarter 2008 Financial Results 5Rosetta Genomics Reports Second Quarter 2008 Financial Results 6Rosetta Genomics Reports Second Quarter 2008 Financial Results 7Rosetta Genomics Reports Second Quarter 2008 Financial Results 8Rosetta Genomics Reports Second Quarter 2008 Financial Results 9Rosetta Genomics Reports Second Quarter 2008 Financial Results 10Rosetta Genomics Reports Second Quarter 2008 Financial Results 11Rosetta Genomics Reports Second Quarter 2008 Financial Results 12VNUS Corrects Second Quarter 2008 Results and Revises Full Year 2008 Guidance 2VNUS Corrects Second Quarter 2008 Results and Revises Full Year 2008 Guidance 3VNUS Corrects Second Quarter 2008 Results and Revises Full Year 2008 Guidance 4
Hamster serum from Equitech-Bio
... in several versions. The Captiva 0.2 um and 0.45 ...itated protein samples for LC/MS analysis. Filtrat... clogging of expensive HPLC columns. The Captiva 1...ates are designed for clarifying highly particle-l...
...ith CyScribe GFX Purification Kit, 25 reactions. F...-labeled cDNA.Optimized reagents are packaged toge...lexible and optimized protocols can be used for pe...5-labeled nucleotides.Reliable purification using ...
...m - dUTP with CyScribe GFX Purification Kit, 50 re...3- and Cy5-labeled cDNA.Optimized reagents are pac...fication.Flexible and optimized protocols can be u...Cy3- or Cy5-labeled nucleotides.Reliable purificat...
Biology Products: